MDM2 and Miyoshi myopathy: The aim of this pilot study was to investigate the relationship between the immunohistochemical expression of MDM2 and NF-κB proteins in CD138-positive plasma cells before and after induction therapy with bortezomib-based therapies in patients with newly diagnosed MM, and to evaluate the potential association of these proteins with standard clinical parameters and selected prognostic factors.